Tag Archives: Nikola Tesla

Getting erased from the mRNA/COVID-19 story

Nathan Vardi’s August 17, 2021 article for Forbes magazine about Ian MacLachlan and the delivery system for mRNA vaccines tells a type of story I’ve more often seen in history books. It is reminiscent of the Thomas Edison and Nikola Tesla story of electricity. One gets all the glory while the other is largely forgotten.

I’m especially interested as much of this concerns players in the local (Vancouver, British Columbia, Canada) biotechnology scene. Vardi’s August 17, 2021 article sets the scene,

“The whole mRNA platform is not how to build an mRNA molecule; that’s the easy thing,” Bourla [Pfizer CEO Albert Bourla] says. “It is how to make sure the mRNA molecule will go into your cells and give the instructions.” 

Yet the story of how Moderna, BioNTech and Pfizer managed to create that vital delivery system has never been told. It’s a complicated saga involving 15 years of legal battles and accusations of betrayal and deceit. [emphases mine] What is clear is that when humanity needed a way to deliver mRNA to human cells to arrest the pandemic, there was only one reliable method available—and it wasn’t one originated in-house by Pfizer, Moderna, BioNTech or any of the other major vaccine companies. 

A months-long investigation by Forbes reveals that the scientist most responsible for this critical delivery method is a little-known 57-year-old Canadian biochemist named Ian MacLachlan. As chief scientific officer of two small companies, Protiva Biotherapeutics and Tekmira Pharmaceuticals, MacLachlan led the team that developed this crucial technology. Today, though, few people—and none of the big pharmaceutical companies—openly acknowledge his groundbreaking work, and MacLachlan earns nothing from the technology he pioneered. 

I have three stories (on this blog) mentioning Tekmira (all from 2014 or 2015) and none mentioning Protiva nor, for that matter, Ian MacLachlan.

Back to Vardi’s August 17, 2021 article,

Moderna Therapeutics vigorously disputes the idea that its mRNA vaccine uses MacLachlan’s delivery system, and BioNTech, the vaccine maker partnered with Pfizer, talks about it carefully. Legal proceedings are pending, and big money is at stake. 

Moderna, BioNTech and Pfizer are on their way to selling $45 billion worth of vaccines in 2021. They don’t pay a dime to MacLachlan. Other coronavirus vaccine makers, such as Gritstone Oncology, have recently licensed MacLachlan’s Protiva-Tekmira delivery technology for between 5% and 15% of product sales. MacLachlan no longer has a financial stake in the technology, but a similar royalty on the Moderna and Pfizer-BioNTech vaccines could yield as much as $6.75 billion in 2021 alone. …

Vardi provides evidence (Note: A link has been removed from the August 17, 2021 article excerpt,

Despite their denials, scientific papers and regulatory documents filed with the FDA [US Food and Drug Administration] show that both Moderna and Pfizer-BioNTech’s vaccines use a delivery system strikingly similar to what MacLachlan and his team created—a carefully formulated four-lipid component that encapsulates mRNA in a dense particle through a mixing process involving ethanol and a T-connector apparatus. 

For years, Moderna claimed it was using its own proprietary delivery system, but when it came time for the company to test its Covid-19 vaccine in mice, it used the same four kinds of lipids as MacLachlan’s technology, in identical ratios. 

According to Vardi’s LinkedIn profile: “I am a senior editor at Forbes, where I am responsible for the coverage of hedge funds, private equity, and other big investors. I lead investigative reporting efforts and have written 20 cover stories for Forbes Magazine,” he does not appear to have any medical or bioscience expertise (Bachelor of Journalism from Carleton University [Canada] and Masters of International Affairs from Columbia University [US].) Presumably someone he consulted or someone on his team provided the skills necessary for analyzing the scientific papers and documents.

You may recognize this scientist (from the August 17, 2021 article),

Not everyone ignores MacLachlan. “A lot of credit goes to Ian MacLachlan for the LNP [lipid nanoparticle],” says Katalin Karikó, [emphasis mine] the scientist who laid the groundwork for mRNA therapies before joining BioNTech in 2013. But Karikó, now a frontrunner for a Nobel Prize, is angry that MacLachlan didn’t do more to help her use his delivery system to build her own mRNA company years ago. “[MacLachlan] might be a great scientist, but he lacked vision,” she says.

I have more about Karikó and her role in the mRNA vaccine story here in a March 5, 2021 posting.

As for MacLachlan’s start (from the August 17, 2021 article),

… With a Ph.D. in biochemistry, MacLachlan joined Inex in 1996, his first job after completing a postdoctoral fellowship in a gene lab at the University of Michigan. 

Inex was cofounded by its chief scientific officer, Pieter Cullis, now 75, a long-haired physicist who taught at the University of British Columbia. From his perch there Cullis started several biotechs, cultivating an elite community of scientists that made Vancouver a hotbed of lipid chemistry. 

As companies rise and fall with intellectual property being assigned to one company or other, legal brawls ensue. This was the time that Karikó came knocking on the door, from the August 17, 2021 article,

It was in the midst of all this furious legal fighting that Hungarian biochemist Katalin Karikó first showed up at MacLachlan’s door. Karikó was early to grasp that MacLachlan’s delivery system held the key to unlocking the potential of mRNA therapies. As early as 2006, she began sending letters to MacLachlan urging him to encase her groundbreaking chemically altered mRNA in his four-lipid delivery system. Embroiled in litigation, MacLachlan passed on her offer. 

Karikó didn’t give up easily. In 2013, she flew to meet with Tekmira’s executives, offering to relocate to Vancouver and work directly under MacLachlan. Tekmira passed. “Moderna, BioNTech and CureVac all wanted me to work for them, but my number one choice, Tekmira, didn’t,” says Karikó, who took a job at BioNTech in 2013. 

By this time, Moderna CEO Stéphane Bancel [emphasis mine] was also trying to solve the delivery puzzle. Bancel held discussions with Tekmira about collaborating, but talks stalled. At one point, Tekmira indicated it wanted at least $100 million up front, plus royalties, to strike a deal.

Instead, Moderna partnered with Madden [Thomas Madden], who was still working with Cullis at their drug delivery company, Acuitas Therapeutics.  …

I have been wondering why Acuitas Therapeutics hasn’t been getting all that much attention in the hyperbolic discussions about British Columbia’s (or Vancouver’s) thriving biotechnology scene. (I’ll have more about the ‘scene’ in a later posting.) Perhaps all this legal wrangling is not considered helpful when bragging. (I do have a November 12, 2020 post, which features Acuitas, an interview with its president and chief executive office Dr. Thomas Madden, and an explanation of their technology.)

As for Moderna, I have a special interest as the company has announced plans to open a production facility here in Canada and one of Moderna’s founders is Canadian, Derek Rossi. (He too is mentioned in the March 5, 2021 posting, scroll down to the ‘Entrepreneurs rush in’ subhead; he is not an altogether happy camper.)

Rossi has opinions on how we should be doing things here as noted in a June 17, 2021 article by Barbara Shecter for the Financial Post (Moderna founder says Canada needs to build a biotech hub to avoid ‘getting caught with its pants down next time’). Thank you, Mr. Rossi. (I’m more familiar with clusters than hubs [hubs were a popular topic of conversation about 20 years ago but in Canada we seem more interested in clusters; see John Newbigin’s “Hubs, clusters and regions” on britishcouncil.org for a description of the differences].)

As for Moderna’s response to all of the legal wrangling over mRNA delivery systems, from Vardi’s August 17, 2021 article,

Moderna pursued a different strategy. It filed lawsuits with the U.S. Patent and Trademark Office seeking to nullify a series of patents related to MacLachlan’s delivery system, now controlled by Genevant. But in July 2020, as Moderna was pushing its vaccine through clinical trials, an adjudicative body largely upheld the most important patent claims. (Moderna is appealing.)

I highly recommend reading Vardi’s August 17, 2021 article as I have not done justice to all of the ‘ins and outs’ of the story.

You can see how thoroughly MacLachlan has been erased form the lipid nanoparticle delivery system/COVID-19 vaccine story in this May 24 ,2021 posting (Lipid nanoparticles: The underrated invention behind the vaccine revolution) by Nada Salem at the Science Borealis blog. It is largely a description of the technology and in the last two paragraphs a history of its development with no mention of MacLachlan or any of his companies.

One last thought, I wonder how Vardi found out about MacLachlan. Could someone have brought the story to his attention and who might that have been?

Antiviral, antibacterial surface for reducing spread of infectious diseases

In the past several years, scientists have created antibacterial surfaces by fabricating materials with specific types of nanostructures. According to a May 27, 2020 news item on Nanowerk, scientists have now been able to add antiviral properties (Note: A link has been removed),

The novel coronavirus pandemic has caused an increased demand for antimicrobial treatments that can keep surfaces clean, particularly in health care settings. Although some surfaces have been developed that can combat bacteria, what’s been lacking is a surface that can also kill off viruses.

Now, researchers have found a way to impart durable antiviral and antibacterial properties to an aluminum alloy used in hospitals, according to a report in ACS Biomaterials Science & Engineering (“Antiviral and Antibacterial Nanostructured Surfaces with Excellent Mechanical Properties for Hospital Applications”).

A May 27, 2020 American Chemical Society (ACS) news release (also on EurekAlert), which originated the news item, describes the problem and the proposed solution,

Among other mechanisms, viruses and bacteria can spread when a person touches a site where germs have settled, such as a doorframe, handrail or medical device. A healthy person can often fight off these bugs, but hospital patients can be more vulnerable to infection. The number of hospital-acquired infections has been on the decline in the U.S., but they still cause tens of thousands of deaths every year, according to the U.S. Department of Health and Human Services. Chemical disinfectants or coatings containing hydrophobic compounds, silver ions or copper can reduce infectious contaminants on surfaces, but these treatments don’t last. However, nature has developed its own solutions for battling microorganisms, including microscopic structural features that render some insect wings lethal to bacteria. Scientists have replicated this effect by forming surfaces covered with minute pillars and other shapes that distort and kill bacterial cells. But Prasad Yarlagadda and colleagues wanted to inactivate viruses as well as bacteria, so they set out to generate a novel nanoscale topography on long-lasting, industrially relevant materials.

The team experimented with disks of aluminum 6063, which is used in doorframes, window panels, and hospital and medical equipment. Etching the disks with sodium hydroxide for up to 3 hours changed the initially smooth, hydrophobic surface into a ridged, hydrophilic surface. Bacteria or viruses were then applied to the etched disks. Most of the Pseudomonas aeruginosa and Staphylococcus aureus bacteria were inactivated after 3 hours on the surface, while viability of common respiratory viruses dropped within 2 hours; both results were better than with plastic or smooth aluminum surfaces. The disks retained their effectiveness even after tests designed to mimic hospital wear and tear. The researchers note this is the first report to show combined antibacterial and antiviral properties of a durable, nanostructured surface that has the potential to stop the spread of infections arising from physical surfaces in hospitals. This strategy could be extended to surfaces in other public areas, such as cruise ships, planes and airports, they say. The team is now studying the effects of their nano-textured aluminum surfaces on the novel coronavirus.

This approach reminds me of Sharklet, a company fabricating a material designed to mimic a shark’s skin which is naturally antibacterial due to the nanostructures on its skin (see my September 18, 2014 posting).

More about Sharklet later. First, here’s a link to and a citation for the paper about this latest work,

Antiviral and Antibacterial Nanostructured Surfaces with Excellent Mechanical Properties for Hospital Applications by Jafar Hasan, Yanan Xu, Tejasri Yarlagadda, Michael Schuetz, Kirsten Spann, and Prasad KDV Yarlagadda. ACS Biomater. Sci. Eng. 2020, XXXX, XXX, XXX-XXX DOI: https://doi.org/10.1021/acsbiomaterials.0c00348 Publication Date:May 7, 2020 Copyright © 2020 American Chemical Society

This paper is behind a paywall.

Business and science: a Sharklet update

You can find the Sharklet website here. I wasn’t able to find any news about recent business deals other than the company’s acquisition by Peaceful Union in May 2017. From a May 17, 2017 Sharklet news release on Business Wire (and on the company website here),

Sharklet Technologies, Inc., a biotechnology company lauded for the creation and commercialization of Sharklet®, the world’s first micro-texture that inhibits bacterial growth on surfaces, has announced that it has completed a financing event led by Peaceful Union, an equity medical device firm in Hangzhou, China. Terms of the transaction were not disclosed.

The acquisition of the company will enable Sharklet Technologies to accelerate the development of Sharklet for medical devices where chemical-free bacterial inhibition is desired as well as high-touch surfaces prone to bacterial contamination. The company also will accelerate development of a newly enhanced wound dressing technology to encourage healing.

Joe Bagan and Mark Spiecker led the transaction structure. “This is an important day for the company and investors,” said Joe Bagan, former board chair, and Mark Spiecker, former CEO. “Our investors will realize a significant transaction while enabling the company to accelerate growth.”

In concert with the investment, Sharklet Technologies founding member, chief technology officer, and Sharklet inventor Dr. Anthony Brennan, will become chairman of the board assuming duties from chairman Joe Bagan and CEO Mark Spiecker.

Interestingly, Bagan and Spiecker are Chief Executive Officer (CEO) and President, respectively at STAQ Pharma. I wonder if there are plans to sell this company too.

Getting back to Sharklet, I found two items of recent origin about business but I cannot speak to the accuracy or trustworthiness of either item. That said, you will find they provide some detail about Sharklet’s new business directions and new business ties.

While Sharklet’s current business associations have a sketchy quality, it seems that’s not unusual in business, especially where new technologies are concerned. For example, the introduction of electricity into homes and businesses was a tumultuous affair as the 2008 book, ‘Power Struggles; Scientific Authority and the Creation of Practical Electricity Before Edison’ by Michael Brian Schiffer makes clear, from the MIT [Massachusetts Institute of Technology] Press ‘Power Struggles’ webpage,

In 1882, Thomas Edison and his Edison Electric Light Company unveiled the first large-scale electrical system in the world to light a stretch of offices in a city. … After laying out a unified theoretical framework for understanding technological change, Schiffer presents a series of fascinating case studies of pre-Edison electrical technologies, including Volta’s electrochemical battery, the blacksmith’s electric motor, the first mechanical generators, Morse’s telegraph, the Atlantic cable, and the lighting of the Capitol dome. Schiffer discusses claims of “practicality” and “impracticality” (sometimes hotly contested) made for these technologies, and examines the central role of the scientific authority—in particular, the activities of Joseph Henry, mid-nineteenth-century America’s foremost scientist—in determining the fate of particular technologies. These emerging electrical technologies formed the foundation of the modern industrial world. Schiffer shows how and why they became commercial products in the context of an evolving corporate capitalism in which conflicting judgments of practicality sometimes turned into power struggles. [emphases mine]

Even given that the book’s focus is pre-Edison electricity, how do you mention Edison himself without even casually mentioning Nikola Tesla and George Westinghouse in the book’s overview? Getting back to my point, emerging technologies do not emerge easily.

Teslaphoresis; self-assembling materials from a distance

Getting carbon nanotubes to self-assemble from a distance is possible according to an April 14, 2016 news item on ScienceDaily,

Scientists at Rice University have discovered that the strong force field emitted by a Tesla coil causes carbon nanotubes to self-assemble into long wires, a phenomenon they call “Teslaphoresis.”

An April 14, 2016 Rice University (US) news release, (also on EurekAlert) which originated the news item, expands on the theme,

Cherukuri [Rice chemist Paul Cherukuri] sees this research as setting a clear path toward scalable assembly of nanotubes from the bottom up.

The system works by remotely oscillating positive and negative charges in each nanotube, causing them to chain together into long wires. Cherukuri’s specially designed Tesla coil even generates a tractor beam-like effect as nanotube wires are pulled toward the coil over long distances.

This force-field effect on matter had never been observed on such a large scale, Cherukuri said, and the phenomenon was unknown to Nikola Tesla, who invented the coil in 1891 with the intention of delivering wireless electrical energy.

“Electric fields have been used to move small objects, but only over ultrashort distances,” Cherukuri said. “With Teslaphoresis, we have the ability to massively scale up force fields to move matter remotely.”

The researchers discovered that the phenomenon simultaneously assembles and powers circuits that harvest energy from the field. In one experiment, nanotubes assembled themselves into wires, formed a circuit connecting two LEDs and then absorbed energy from the Tesla coil’s field to light them.

Cherukuri realized a redesigned Tesla coil could create a powerful force field at distances far greater than anyone imagined. His team observed alignment and movement of the nanotubes several feet away from the coil. “It is such a stunning thing to watch these nanotubes come alive and stitch themselves into wires on the other side of the room,” he said.

Nanotubes were a natural first test material, given their heritage at Rice, where the HiPco production process was invented. But the researchers envision many other nanomaterials can be assembled as well.

Lindsey Bornhoeft, the paper’s lead author and a biomedical engineering graduate student at Texas A&M University, said the directed force field from the bench-top coil at Rice is restricted to just a few feet. To examine the effects on matter at greater distances would require larger systems that are under development. Cherukuri suggested patterned surfaces and multiple Tesla coil systems could create more complex self-assembling circuits from nanoscale-sized particles.

Cherukuri and his wife, Tonya, also a Rice alum and a co-author of the paper, noted that their son Adam made some remarkable observations while watching videos of the experiment. “I was surprised that he noticed patterns in nanotube movements that I didn’t see,” Cherukuri said. “I couldn’t make him an author on the paper, but both he and his little brother John are acknowledged for helpful discussions.”

Cherukuri knows the value of youthful observation — and imagination — since he started designing Tesla coils as a teen. “I would have never thought, as a 14-year-old kid building coils, that it was going to be useful someday,” he said.

Cherukuri and his team self-funded the work, which he said made it more meaningful for the group. “This was one of the most exciting projects I’ve ever done, made even more so because it was an all-volunteer group of passionate scientists and students. But because Rice has this wonderful culture of unconventional wisdom, we were able to make an amazing discovery that pushes the frontiers of nanoscience.”

The teammates look forward to seeing where their research leads. “These nanotube wires grow and act like nerves, and controlled assembly of nanomaterials from the bottom up may be used as a template for applications in regenerative medicine,” Bornhoeft said.

“There are so many applications where one could utilize strong force fields to control the behavior of matter in both biological and artificial systems,” Cherukuri said. “And even more exciting is how much fundamental physics and chemistry we are discovering as we move along. This really is just the first act in an amazing story.”

Rice University has produced a video featuring the research and the researchers,

Here’s a link to and a citation for the paper,

Teslaphoresis of Carbon Nanotubes by Lindsey R. Bornhoeft, Aida C. Castillo, Preston R. Smalley, Carter Kittrell, Dustin K. James, Bruce E. Brinson, Thomas R. Rybolt, Bruce R. Johnson, Tonya K. Cherukuri†, and Paul Cherukuri. ACS Nano, Article ASAP DOI: 10.1021/acsnano.6b02313 Publication Date (Web): April 13, 2016

Copyright © 2016 American Chemical Society

This paper is behind a paywall.

The Tesla coil was created by Nikola Tesla, a renowned Serbian-American scientist and engineer.